[3] Nicholls SJ, Tuzcu EM, Sipahi I et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis JAMA 2007 297:499-508
[4] Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther. 2007 5:177-93.
[5] Shepherd J, Hunninghake DB, Stein EA et al. Safety of rosuvastatin. Am J Cardiol. 2004 94:882-8
[6] McAfee AT, Ming EE, Seeger JD et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf. 2006 15:444-53
[7] Goettsch WG, Heintjes EM, Kastelein JJ et al. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study. Pharmacoepidemiol Drug Saf. 2006 15:435-43.
[8] Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006 295:1556-65
AstraZeneca (NYSE: AZN , LSE: AZN)
This press release has been made available on worldwide press communication media for the benefit of correspondents writing for the medical professional press. Differing national legislation, codes of practice, medical practice etc mean that you should contact your local AZ press office to obtain information designed for use in your country. In particular this press release has not been prepared for use in the USA.
For further information please visit: www.AstraZenecaPressOffice.com or contact: Ben Strutt, Global PR Manager, Cardiovascular Therapy Area, AstraZeneca, Tel: +44-(0)-1625-230076, Email: ben.strutt@astrazeneca.com
